Skip to content

Clinical trials

Phase 3 Lung Diseases trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lung Diseases Phase: Phase 3 Clear all

123 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20011
20023
20034
20041
20053
20062
20072
20081
20094
20105
20125
20133
20149
20155
20165
20176
20183
20196
20206
20212
20223
20233
20244
20257
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed77
Terminated17
Recruiting13
Unknown status7
Withdrawn4
Active, not recruiting3
Not yet recruiting1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca18
National Heart, Lung, and Blood Institute (NHLBI)16
Novartis Pharmaceuticals8
InterMune3
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.3
United Therapeutics3
BioNTech SE2
Fundación GECP2
Imam Abdulrahman Bin Faisal University2
Johns Hopkins Bloomberg School of Public Health2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lung Diseases123
Respiratory Tract Diseases45
Lung Diseases, Obstructive28
Asthma23
Pulmonary Disease, Chronic Obstructive19
Bronchial Diseases18
Carcinoma, Non-Small-Cell Lung13
Lung Neoplasms11
Respiratory Distress Syndrome11
Respiratory Tract Infections11

Trials

Showing 51 to 75 of 123. Each trial links to its page on Pharma Observatory.

23 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.